The belimumab + rituximab group also showed a trend toward delayed repopulation of total B cells, with median levels of total B cells only returning to a similar level as the monotherapy groups at week 52, following belimumab discontinuation at week 24.
← all excerpts
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.
1
—
—